1. Bioinformatics Partnering Terms and Agreements
The Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and
unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading
healthcare companies.
Trends in bioinformatics partnering deals Deal terms analysis Partnering agreement structure Partnering
contract documents Top deals by value Most active dealmakers Average deal terms for bioinformatics The
Bioinformatics Partnering Terms and Agreements report provides comprehensive understanding and
unprecedented access to the bioinformatics partnering deals and agreements entered into by the worlds leading
healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter bioinformatics
partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option
right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting with
collaborative R&D, and commercialization of outcomes.
This report provides details of the latest bioinformatics agreements announced in the healthcare sectors.
Bioinformatics is the application of computer science and information technology to the field of biology and
medicine. Bioinformatics deals with algorithms, databases, information systems, web technologies, artificial
intelligence, information and computation theory, software engineering, data mining, image processing,
modeling, simulation, signal processing, discrete mathematics, control systems, and statistics, for generating
new knowledge of biology and medicine.
Bioinformatics deals have increased in terms of popularity for partnering in the past decade, as computing
power has been embraced in order to speed up the discovery, evaluation and clinical assessment processes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight
into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst
many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of
how payments are triggered – contract documents provide this insight where press releases and
databases do not.
This report contains a comprehensive listing of all bioinformatics partnering deals announced since January
2007, including financial terms where available, including over 1500 links to online deal records of actual
bioinformatics partnering deals as disclosed by the deal parties. In addition, where available, records include
contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of bioinformatics dealmaking and business activities.
Bioinformatics Partnering Terms and Agreements

2. Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an overview of the trends in bioinformatics dealmaking since 2007, including details of
average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading bioinformatics deals since 2007. Deals are listed by headline
value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the
deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary
followed by a comprehensive listing of bioinformatics deals, as well as contract documents available in the
public domain. Where available, each deal title links via Weblink to an online version of the actual contract
document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of bioinformatics partnering deals signed and
announced since January 2007, where a contract document is available in the public domain. The chapter is
organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and
specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by bioinformatics partnering company A-Z ,
deal type definitions and bioinformatics partnering agreements example. Each deal title links via Weblink to
an online version of the deal record and where available, the contract document, providing easy access to each
contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in bioinformatics
partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of bioinformatics technologies and products.
Bioinformatics Partnering Terms and Agreements provides the reader with the following key benefits:
In-depth understanding of bioinformatics deal trends since 2007 Access to headline, upfront, milestone and
royalty data Analysis of the structure of bioinformatics agreements with numerous real life case studies
Comprehensive access to over 1500 actual vaccine contracts entered into by the world’s biopharma
companies Detailed access to actual bioinformatics contracts enter into by the leading fifty bigpharma
companies Insight into the terms included in a bioinformatics agreement, together with real world clause
examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to
assess suitability of your proposed deal terms for partner companies Report scope
Bioinformatics Partnering Terms and Agreements is intended to provide the reader with an in-depth
understanding and access to bioinformatics trends and structure of deals entered into by leading companies
worldwide.
Bioinformatics Partnering Terms and Agreements

3. Bioinformatics Partnering Terms and Agreements includes:
Trends in bioinformatics dealmaking in the biopharma industry since 2007 o Analysis of bioinformatics deal
structure Access to headline, upfront, milestone and royalty data o Case studies of real-life bioinformatics
deals o Access to over 1500 bioinformatics contract documents The leading bioinformatics deals by value
since 2005 o Most active bioinformatics dealmakers since 2007 The leading bioinformatics partnering
resources In Bioinformatics Partnering Terms and Agreements, the available contracts are listed by: o
Company A-Z o Headline value Stage of development at signing o Deal component type Specific therapy
target Each deal title links via Weblink to an online version of the deal record and where available, the
contract document, providing easy access to each contract document on demand. The Bioinformatics
Partnering Terms and Agreements report provides comprehensive access to available deals and contract
documents for over 1,500 bioinformatics deals. Analyzing actual contract agreements allows assessment of the
following:
What are the precise bioinformatics rights granted or optioned? What is actually granted by the agreement to
the partner company? What exclusivity is granted? What is the payment structure for the deal? o How are
sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are
IPRs handled and owned? o Who is responsible for commercialization? Who is responsible for development,
supply, and manufacture? How is confidentiality and publication managed? o How are disputes to be
resolved? Under what conditions can the deal be terminated? o What happens when there is a change of
ownership? What sublicensing and subcontracting provisions have been agreed? o Which boilerplate clauses
does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type
to deal type? Which jurisdiction does the company insist upon for agreement law?
table Of Content
executive Summary
chapter 1 – Introduction
chapter 2 – Trends In Bioinformatics Dealmaking
2.1. Introduction
2.2. Bioinformatics Partnering Over The Years
2.3. Bigpharma Bioinformatics Dealmaking Activity
2.4. Bigpharma Not Active In Bioinformatics Partnering
2.5. Bioinformatics Partnering By Deal Type
2.6. Bioinformatics Partnering By Stage Of Development
2.7. Bioinformatics Partnering By Disease Type
2.8. Average Deal Terms For Bioinformatics Partnering
2.8.1 Bioinformatics Partnering Headline Values
2.8.2 Bioinformatics Deal Upfront Payments
Bioinformatics Partnering Terms and Agreements

4. 2.8.3 Bioinformatics Deal Milestone Payments
2.8.4 Bioinformatics Royalty Rates
chapter 3 – Leading Bioinformatics Deals
3.1. Introduction
3.2. Top Bioinformatics Deals By Value
3.3. Top Bioinformatics Deals Involving Bigpharma
chapter 4 – Bigpharma Bioinformatics Deals
4.1. Introduction
4.2. How To Use Bigpharma Bioinformatics Partnering Deals
4.3. Bigpharma Bioinformatics Partnering Company Profiles
abbott
allergan
amgen
astellas
astrazeneca
baxter International
bayer
biogen Idec
boehringer Ingelheim
bristol-myers Squibb
daiichi Sankyo
eisai
eli Lilly
galderma
glaxosmithkline
grifols
hospira 73
johnson & Johnson
merck & Co
merck Kgaa
mitsubishi Tanabe
novartis
novo Nordisk
otsuka
pfizer
purdue
roche
sanofi
servier
shire
Bioinformatics Partnering Terms and Agreements

5. takeda
teva
ucb
valeant
chapter 5 – Bioinformatics Dealmaking Directory
5.1. Introduction
5.2. By Stage Of Development
discovery
formulation
marketed
phase I
phase Ii
phase Iii
preclinical
regulatory
5.3. By Deal Type
asset Purchase
bigpharma Outlicensing
co-development
collaborative R&d
co-market
contract Service
co-promotion
crada
cross-licensing
development
distribution
equity Purchase
evaluation
grant
interests
joint Venture
licensing
litigation
loan
manufacturing
manufacturing - Oem
marketing
option
promotion
research
Bioinformatics Partnering Terms and Agreements

6. settlement
spin Out
sub-license
supply
technology Transfer
termination
5.4. By Therapy Area
anaesthetics
breast
cardiovascular
central Nervous System
dental
dermatology
gastrointestinal
genetic Disorders
genitourinary
gynaecology
hematology
hospital Care
immunology
infectives
metabolic
musculoskeletal
obstetrics
oncology
ophthalmics
pediatrics
psychiatry
public Health
respiratory
sensory Organs
sexual Health
chapter 6 – Partnering Resource Center
6.1. Online Partnering
6.2. Partnering Events
6.3. Further Reading On Dealmaking
about Wildwood Ventures
current Partnering
current Agreements
current Reports
recent Report Titles From Current Partnering
order Form – Reports
Bioinformatics Partnering Terms and Agreements

7. About Us:
Transparency Market Research is a market intelligence company providing global business information
reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of
Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the latest and the most reliable information
indispensable for businesses to sustain a competitive edge.
Contact:
ResearchMoz
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Blog: http://researchmoz.blogspot.com/
Website: http://www.researchmoz.us/
Bioinformatics Partnering Terms and Agreements